Derivation of the Immortalized Cell Line UM51-PrePodo-hTERT and Its Responsiveness to Angiotensin II and Activation of the RAAS Pathway.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
17 01 2023
Historique:
received: 17 11 2022
revised: 12 01 2023
accepted: 14 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 15 2 2023
Statut: epublish

Résumé

Recent demographic studies predict there will be a considerable increase in the number of elderly people within the next few decades. Aging has been recognized as one of the main risk factors for the world's most prevalent diseases such as neurodegenerative disorders, cancer, cardiovascular disease, and metabolic diseases. During the process of aging, a gradual loss of tissue volume and organ function is observed, which is partially caused by replicative senescence. The capacity of cellular proliferation and replicative senescence is tightly regulated by their telomere length. When telomere length is critically shortened with progressive cell division, cells become proliferatively arrested, and DNA damage response and cellular senescence are triggered, whereupon the "Hayflick limit" is attained at this stage. Podocytes are a cell type found in the kidney glomerulus where they have major roles in blood filtration. Mature podocytes are terminal differentiated cells that are unable to undergo cell division in vivo. For this reason, the establishment of primary podocyte cell cultures has been very challenging. In our present study, we present the successful immortalization of a human podocyte progenitor cell line, of which the primary cells were isolated directly from the urine of a 51-year-old male. The immortalized cell line was cultured over the course of one year (~100 passages) with high proliferation capacity, endowed with contact inhibition and P53 expression. Furthermore, by immunofluorescence-based expression and quantitative real-time PCR for the podocyte markers CD2AP, LMX1B, NPHS1, SYNPO and WT1, we confirmed the differentiation capacity of the immortalized cells. Finally, we evaluated and confirmed the responsiveness of the immortalized cells on the main mediator angiotensin II (ANGII) of the renin-angiotensin system (RAAS). In conclusion, we have shown that it is possible to bypass cellular replicative senescence (Hayflick limit) by TERT-driven immortalization of human urine-derived pre-podocyte cells from a 51-year-old African male.

Identifiants

pubmed: 36766685
pii: cells12030342
doi: 10.3390/cells12030342
pmc: PMC9913089
pii:
doi:

Substances chimiques

Angiotensin II 11128-99-7

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Biotechnol. 2015 Nov;33(11):1193-200
pubmed: 26458176
Hum Mol Genet. 1997 Nov;6(12):2011-9
pubmed: 9328464
Biomed Pharmacother. 2017 Oct;94:317-325
pubmed: 28772209
Am J Physiol Renal Physiol. 2002 Jul;283(1):F173-80
pubmed: 12060599
Mol Cell. 1998 Mar;1(4):575-82
pubmed: 9660941
Lab Invest. 1978 Aug;39(2):90-100
pubmed: 682603
Genes Chromosomes Cancer. 2019 Jun;58(6):341-356
pubmed: 30474255
Genes Dev. 1997 Dec 1;11(23):3109-15
pubmed: 9389643
Oncogene. 2012 Nov 15;31(46):4815-27
pubmed: 22310292
Mol Med Rep. 2015 Sep;12(3):4340-4345
pubmed: 26063200
Eur J Cell Biol. 1989 Apr;48(2):313-26
pubmed: 2744005
Toxicol Lett. 1998 Dec 28;102-103:41-5
pubmed: 10022230
Cells. 2022 Jun 21;11(13):
pubmed: 35805209
Kidney Int. 2007 Jul;72(1):26-36
pubmed: 17457377
Cell. 1997 Mar 7;88(5):657-66
pubmed: 9054505
J Cell Biol. 2015 Apr 27;209(2):199-210
pubmed: 25918223
Oncotarget. 2016 Jun 21;7(25):37608-37621
pubmed: 26993771
J Am Coll Cardiol. 2014 Feb 25;63(7):650-658
pubmed: 24269363
Stem Cells. 2012 Aug;30(8):1714-25
pubmed: 22628275
Blood Press. 2003;12(2):70-88
pubmed: 12797627
Oncogene. 2012 Apr 12;31(15):1896-909
pubmed: 21874052
Am J Pathol. 1998 Nov;153(5):1511-20
pubmed: 9811343
Genes Dev. 1997 Nov 1;11(21):2801-9
pubmed: 9353250
Nat Genet. 1999 Dec;23(4):405-12
pubmed: 10581025
Lab Invest. 1984 May;50(5):552-9
pubmed: 6201675
Cell Stem Cell. 2014 Jan 2;14(1):53-67
pubmed: 24332837
Science. 1994 Dec 23;266(5193):2011-5
pubmed: 7605428
Mol Cells. 2002 Jun 30;13(3):351-61
pubmed: 12132573
Nephrology (Carlton). 2006 Aug;11(4):274-81
pubmed: 16889564
Nature. 2015 Oct 22;526(7574):564-8
pubmed: 26444236
Cell. 1985 Dec;43(2 Pt 1):405-13
pubmed: 3907856
JBMR Plus. 2018 May 24;2(5):257-267
pubmed: 30283907
Cancer Res. 2003 Apr 15;63(8):1743-7
pubmed: 12702554
Dev Genet. 1996;18(2):173-9
pubmed: 8934879
J Am Soc Nephrol. 2016 Jun;27(6):1778-91
pubmed: 26586691
Eur J Cancer. 1997 Apr;33(5):787-91
pubmed: 9282118
Science. 1998 Jan 16;279(5349):349-52
pubmed: 9454332
Curr Biol. 1998 Feb 26;8(5):279-82
pubmed: 9501072
Kidney Int. 1992 Mar;41(3):657-64
pubmed: 1573843
J Am Soc Nephrol. 2002 Mar;13(3):630-638
pubmed: 11856766
Nature. 1999 Jul 29;400(6743):464-8
pubmed: 10440377
Annu Rev Physiol. 2012;74:299-323
pubmed: 22054238
Pediatr Nephrol. 1987 Jul;1(3):385-92
pubmed: 3153305
Am J Nephrol. 2008;28(3):500-7
pubmed: 18204248
J Histochem Cytochem. 1991 Aug;39(8):1047-56
pubmed: 1856454
JAMA Intern Med. 2018 Dec 1;178(12):1681-1690
pubmed: 30422153
Front Endocrinol (Lausanne). 2014 Oct 01;5:148
pubmed: 25324828
Development. 1993 Dec;119(4):1329-41
pubmed: 8306891
J Cell Biol. 1990 Sep;111(3):1255-63
pubmed: 2202736
J Am Soc Nephrol. 2006 Nov;17(11):2985-91
pubmed: 17035613
Cell. 1997 Aug 22;90(4):785-95
pubmed: 9288757
Sci Rep. 2020 Jan 20;10(1):739
pubmed: 31959818
J Cell Biol. 1997 Oct 6;139(1):193-204
pubmed: 9314539
Cell. 2008 Mar 21;132(6):945-57
pubmed: 18358808
Pediatr Nephrol. 1997 Apr;11(2):133-9
pubmed: 9090649
Curr Opin Nephrol Hypertens. 2011 Jan;20(1):84-8
pubmed: 21076298
Science. 1997 Apr 25;276(5312):561-7
pubmed: 9110970
Anat Embryol (Berl). 1995 Nov;192(5):385-97
pubmed: 8546330
Cells. 2022 Mar 24;11(7):
pubmed: 35406662
Nat Commun. 2015 Oct 23;6:8715
pubmed: 26493500

Auteurs

Lars Erichsen (L)

Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine University Duesseldorf, 40225 Duesseldorf, Germany.

Lea Doris Friedel Kloss (LDF)

Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine University Duesseldorf, 40225 Duesseldorf, Germany.

Chantelle Thimm (C)

Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine University Duesseldorf, 40225 Duesseldorf, Germany.

Martina Bohndorf (M)

Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine University Duesseldorf, 40225 Duesseldorf, Germany.

Kira Schichel (K)

Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine University Duesseldorf, 40225 Duesseldorf, Germany.

Wasco Wruck (W)

Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine University Duesseldorf, 40225 Duesseldorf, Germany.

James Adjaye (J)

Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine University Duesseldorf, 40225 Duesseldorf, Germany.
EGA Institute for Women's Health, University College London, 86-96 Chenies Mews, London WC1E 6HX, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH